Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Chin J Nat Med ; 19(9): 675-679, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34561078

RESUMO

Buxrugulosides A-E, four lignan glycosides (1-4) and a protocatechuate derivative (5) featuring a rare (N, N-diethyl)methyl amino group at aromatic rings, were obtained from the aerial parts of Buxus rugulosa, which is famous for treating coronary heart disease. Their structures including absolute configurations were elucidated by HRMS, 1D and 2D NMR, and by comparing their CD data with previous reports. Compound 1 was a rare sesquilignan, and all of these compounds were the first example of lignans with (N, N-diethyl)methyl amino group.


Assuntos
Buxus , Lignanas , Glicosídeos , Estrutura Molecular , Extratos Vegetais
2.
World J Microbiol Biotechnol ; 30(3): 847-53, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24233772

RESUMO

To investigate Lactobacillus acidophilus (L. acidophilus) and Bifidobacterium bifidum (B. bifidum) supplementation to triple therapy for Helicobacter pylori (H. pylori) eradication and dynamic changes in intestinal flora in children with H. pylori infection. One hundred H. pylori-infected children were randomly assigned to two groups: treatment group (n = 43), standard triple anti-H. pylori therapy plus probiotics of L. acidophilus and B. bifidum for 2 weeks followed by taking probiotics for another 4 weeks; control group (n = 45), standard triple anti-H. pylori therapy for 6 weeks. After 6-week treatment, ¹³C-urease breath test was performed and side effects were monitored during the observation period. Quantitative PCR with 16S rRNA-gene-targeted species-specific primers was carried out for the analysis of human intestinal B. bifidum, L. acidophilus, and Escherichia coli (E. coli). As expected, treatment group could significantly enhance the H. pylori eradication rate (83.7 vs. 64.4 %, P < 0.05). B. bifidum, L. acidophilus, and E. coli showed no statistical difference before or after therapy in the treatment group. The number of B. bifidum and L. acidophilus was significantly decreased after 2-week treatment in the control group, but after 6-week treatment it significantly increased and nearly returned to the level before treatment. The number of E. coli increased significantly after 2-week treatment, while after 6-week treatment, it nearly decreased to the level before treatment. L. acidophilus and B. bifidum supplementation is effective for H. pylori eradication compared with triple therapy alone.


Assuntos
Antibacterianos/administração & dosagem , Bifidobacterium/crescimento & desenvolvimento , Trato Gastrointestinal/microbiologia , Infecções por Helicobacter/terapia , Lactobacillus acidophilus/crescimento & desenvolvimento , Probióticos/administração & dosagem , Carga Bacteriana , Bifidobacterium/isolamento & purificação , Terapia Biológica/métodos , Testes Respiratórios , Criança , Pré-Escolar , Quimioterapia Combinada/métodos , Escherichia coli/efeitos dos fármacos , Escherichia coli/crescimento & desenvolvimento , Escherichia coli/isolamento & purificação , Feminino , Infecções por Helicobacter/diagnóstico , Helicobacter pylori/efeitos dos fármacos , Helicobacter pylori/crescimento & desenvolvimento , Helicobacter pylori/isolamento & purificação , Humanos , Lactobacillus acidophilus/isolamento & purificação , Masculino , RNA Ribossômico 16S/genética , Reação em Cadeia da Polimerase em Tempo Real , Resultado do Tratamento , Urease/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA